Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Endocrinology ; 155(11): 4157-67, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25137027

ABSTRACT

Although the antidiabetic effects of leptin require intact neuronal melanocortin signaling in rodents with uncontrolled diabetes (uDM), increased melanocortin signaling is not sufficient to mimic leptin's glucose-lowering effects. The current studies were undertaken to clarify the role of melanocortin signaling in leptin's ability to correct metabolic and neuroendocrine disturbances associated with uDM. To accomplish this, bilateral cannulae were implanted in the lateral ventricle of rats with streptozotocin-induced diabetes, and leptin was coinfused with varying doses of the melanocortin 3/4 receptor (MC3/4R) antagonist, SHU9119. An additional cohort of streptozotocin-induced diabetes rats received intracerebroventricular administration of either the MC3/4R agonist, melanotan-II, or its vehicle. Consistent with previous findings, leptin's glucose-lowering effects were blocked by intracerebroventricular SHU9119. In contrast, leptin-mediated suppression of hyperglucagonemia involves both melanocortin dependent and independent mechanisms, and the degree of glucagon inhibition was associated with reduced plasma ketone body levels. Increased central nervous system melanocortin signaling alone fails to mimic leptin's ability to correct any of the metabolic or neuroendocrine disturbances associated with uDM. Moreover, the inability of increased melanocortin signaling to lower diabetic hyperglycemia does not appear to be secondary to release of the endogenous MC3/4R inverse agonist, Agouti-related peptide (AgRP), because AgRP knockout mice did not show increased susceptibility to the antidiabetic effects of increased MC3/4R signaling. Overall, these data suggest that 1) AgRP is not a major driver of diabetic hyperglycemia, 2) mechanisms independent of melanocortin signaling contribute to leptin's antidiabetic effects, and 3) melanocortin receptor blockade dissociates leptin's glucose-lowering effect from its action on other features of uDM, including reversal of hyperglucagonemia and ketosis, suggesting that brain control of ketosis, but not blood glucose levels, is glucagon dependent.


Subject(s)
Diabetes Mellitus, Experimental/drug therapy , Leptin/therapeutic use , Melanocortins/metabolism , Receptors, Melanocortin/physiology , Animals , Diabetes Mellitus, Experimental/metabolism , Male , Melanocyte-Stimulating Hormones/pharmacology , Mice , Mice, Knockout , Neurosecretory Systems/drug effects , Rats , Rats, Wistar , Receptors, Melanocortin/antagonists & inhibitors , Signal Transduction/physiology
2.
Am J Physiol Endocrinol Metab ; 304(7): E734-46, 2013 Apr 01.
Article in English | MEDLINE | ID: mdl-23384771

ABSTRACT

Recent advances in human brown adipose tissue (BAT) imaging technology have renewed interest in the identification of BAT activators for the treatment of obesity and diabetes. In uncontrolled diabetes (uDM), activation of BAT is implicated in glucose lowering mediated by intracerebroventricular (icv) administration of leptin, which normalizes blood glucose levels in streptozotocin (STZ)-induced diabetic rats. The potent effect of icv leptin to increase BAT glucose uptake in STZ-diabetes is accompanied by the return of reduced plasma thyroxine (T4) levels and BAT uncoupling protein-1 (Ucp1) mRNA levels to nondiabetic controls. We therefore sought to determine whether activation of thyroid hormone receptors is sufficient in and of itself to lower blood glucose levels in STZ-diabetes and whether this effect involves activation of BAT. We found that, although systemic administration of the thyroid hormone (TR)ß-selective agonist GC-1 increases energy expenditure and induces further weight loss in STZ-diabetic rats, it neither increased BAT glucose uptake nor attenuated diabetic hyperglycemia. Even when GC-1 was administered in combination with a ß(3)-adrenergic receptor agonist to mimic sympathetic nervous system activation, glucose uptake was not increased in STZ-diabetic rats, nor was blood glucose lowered, yet this intervention potently activated BAT. Similar results were observed in animals treated with active thyroid hormone (T3) instead of GC-1. Taken together, our data suggest that neither returning normal plasma thyroid hormone levels nor BAT activation has any impact on diabetic hyperglycemia, and that in BAT, increases of Ucp1 gene expression and glucose uptake are readily dissociated from one another in this setting.


Subject(s)
Adipose Tissue, Brown/metabolism , Diabetes Mellitus, Experimental/metabolism , Glucose/metabolism , Hyperglycemia/metabolism , Sympathetic Nervous System/metabolism , Thermogenesis/physiology , Thyroid Hormone Receptors beta/metabolism , Acetates/pharmacology , Adipose Tissue, Brown/drug effects , Adrenergic beta-3 Receptor Agonists/pharmacology , Animals , Body Composition/drug effects , Diabetes Mellitus, Experimental/complications , Eating/drug effects , Hyperglycemia/drug therapy , Hyperglycemia/etiology , Ion Channels/drug effects , Ion Channels/metabolism , Male , Mitochondrial Proteins/drug effects , Mitochondrial Proteins/metabolism , Phenols/pharmacology , Rats , Rats, Wistar , Receptors, Adrenergic, beta-3/metabolism , Streptozocin , Sympathetic Nervous System/drug effects , Thermogenesis/drug effects , Thyroid Hormone Receptors beta/agonists , Triiodothyronine/pharmacology , Uncoupling Protein 1
SELECTION OF CITATIONS
SEARCH DETAIL
...